Leiomyosarcoma clinical trials at UCLA
2 in progress, 0 open to eligible people
Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
Los Angeles, California and other locations
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Sorry, in progress, not accepting new patients
This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone.
Los Angeles, California
Our lead scientists for Leiomyosarcoma research studies include Vishruth Reddy, MD, PhD.